Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC5 | P28715 | 1/20 | 0.58 |
| ▸ | FEN1 | P39748 | 1/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.55 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.50 |
| ▸ | WNT3A | P56704 | 4/20 | 0.50 |
| ▸ | GSK3B | P49841 | 3/20 | 0.50 |
| ▸ | HPGDS | O60760 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29669998 | 1.00 | ERCC5 (0.58) | ERCC5FEN1PTPN1CTNNB1WNT3A | |
| SCHEMBL30923611 | 0.84 | PTPN1 (0.49) | ERCC5FEN1PTPN1CTNNB1WNT3A | |
| SCHEMBL9409754 | 0.84 | PTPN1 (0.65) | PTPN1GSK3BHPGDSHPGDKMT2A | |
| SCHEMBL15979740 | 0.82 | CTNNB1 (0.68) | ERCC5FEN1CTNNB1WNT3AHPGD | |
| SCHEMBL8735550 | 0.82 | ERCC5 (0.74) | ERCC5FEN1CTNNB1WNT3AHPGD | |
| SCHEMBL30089517 | 0.82 | CTNNB1 (0.68) | ERCC5FEN1CTNNB1WNT3AHPGD | |
| SCHEMBL31619208 | 0.82 | ALDH1A1 (0.60) | PTPN1GSK3BHPGDKMT2ANPC1 | |
| SCHEMBL16706941 | 0.82 | PTPN1 (0.50) | ERCC5FEN1PTPN1CTNNB1WNT3A | |
| SCHEMBL5565924 | 0.81 | ERCC5 (0.52) | ERCC5FEN1CTNNB1WNT3AHPGD | |
| SCHEMBL12876827 | 0.80 | PTPN1 (0.49) | ERCC5FEN1PTPN1CTNNB1WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 334 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115557865-A | Thioether-promoted cysteine-based bioconjugation method | 南京工业大学 | 2023-01-03 | — | — | CN | claimed |
| JP-11343289-A | — | — | None | — | — | JP | disclosed |
| US-20260085046-A1 | Dual Function Compounds For NADPH Oxidase Inhibition And Histone Deacetylase Inhibition | TAIWANJ PHARMACEUTICALS CO LTD (TW) | 2026-03-26 | — | — | US | disclosed |
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | ILDONG PHARMACEUTICAL CO LTD (KR) | 2025-12-25 | — | — | US | disclosed |
| US-12351553-B2 | Process for producing 5-aryl-1H-pyrolle-3-carbonitrile compounds by dehalogenation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-07-08 | — | — | US | disclosed |
| EP-4556476-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | Ildong Pharmaceutical Co., Ltd. (KR) | 2025-05-21 | — | — | EP | disclosed |
| CN-115246826-B | Quaternary ammonium salt isoxazoline compound, its preparation and application as insecticidal and bactericidal agent | 瑞普（天津）生物药业有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-117683026-A | 3-tetrahydrofuran chromone compound and diastereoisomeric divergent preparation method and application thereof | 广州中医药大学(广州中医药研究院) | 2024-03-12 | — | — | CN | disclosed |
| WO-2024014885-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | 일동제약(주) | 2024-01-18 | — | — | WO | disclosed |
| EP-4265613-A1 | BENZENE RING COMPOUND AND USE THEREOF | Nanjing Shijiang Medicine Technology Co., Ltd (CN) | 2023-10-25 | — | — | EP | disclosed |
| US-4683312-A | ANTIDIABETIC AGENTS | ELI LILLY AND COMPANY (US) | 1987-07-28 | — | — | US | disclosed |
| US-4609670-A | ANTIDIABETIC AGENTS | ELI LILLY AND COMPANY (US) | 1986-09-02 | — | — | US | disclosed |
| EP-0182533-A2 | 3-(2-Aryl-2-oxoethyl)-imidazolium salts as hypoglycemic agents | ELI LILLY AND COMPANY (US) | 1986-05-28 | — | — | EP | disclosed |
| US-4406688-A | Herbicidal 4-benzoyl-5-phenacyloxy-pyrazole derivatives, composition and method | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1983-09-27 | — | — | US | disclosed |
| EP-0005783-B1 | IMIDAZO (2.1-B)-(1.3.4)-THIADIAZOLES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN MEDICAMENTS | BAYER AG (DE) | 1981-12-30 | — | — | EP | disclosed |
| US-4265898-A | ANTICOAGULANTS | BAYER AKTIENGESELLSCHAFT (DE) | 1981-05-05 | — | — | US | disclosed |
| EP-0019796-A1 | Propionic acid esters, preparation of these compounds, herbicides containing these compounds as active substances, and the use of such compounds and agents for combating weeds | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1980-12-10 | — | — | EP | disclosed |
| EP-0005783-A1 | Imidazo (2.1-b)-(1.3.4)-thiadiazoles, process for their preparation and their use in medicaments | BAYER AG (DE) | 1979-12-12 | — | — | EP | disclosed |
| US-3988375-A | HERBICIDES | MONSANTO COMPANY (US) | 1976-10-26 | — | — | US | disclosed |
| US-3965181-A | Tricyclic pharmacological agents, intermediates and methods of making | SYNTEX (U.S.A.) INC. (US) | 1976-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085046-A1 | Dual Function Compounds For NADPH Oxidase Inhibition And Histone Deacetylase Inhibition | NOX1, NOX4, CYBB | ERCC5 2843/4885FEN1 1958/4885PTPN1 560/4885 |
| US-12351553-B2 | Process for producing 5-aryl-1H-pyrolle-3-carbonitrile compounds by dehalogenation | CYP51A1, PAH, HPD | ERCC5 4793/4885FEN1 3744/4885PTPN1 2700/4885 |
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | GBA1, PIKFYVE, MAN2B1 | ERCC5 3142/4885FEN1 3309/4885PTPN1 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.